Antral follicle count provides additive information to hormone measures in determining ovarian function in breast cancer survivors

2009 ◽  
Vol 92 (3) ◽  
pp. S183
Author(s):  
H.I. Su ◽  
M.D. Sammel ◽  
C.R. Gracia ◽  
A. DeMichele
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Ovarian Function ◽  
Antral Follicle ◽  
Antral Follicle Count

scholarly journals Antral follicle count provides additive information to hormone measures for determining ovarian function in breast cancer survivors

2011 ◽  
Vol 95 (5) ◽  
pp. 1857-1859 ◽  
Author(s):  
H. Irene Su ◽  
Karine Chung ◽  
Mary D. Sammel ◽  
Clarisa R. Gracia ◽  
Angela DeMichele
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Ovarian Function ◽  
Antral Follicle ◽  
Antral Follicle Count

scholarly journals Fertility preservation and decisional regret in young breast cancer survivors: A longitudinal analysis.

2017 ◽  
Vol 35 (5_suppl) ◽  
pp. 106-106
Author(s):  
Samantha Rose Dewald ◽  
Loki Natarajan ◽  
Irene Su
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Fertility Preservation ◽  
Repeated Measures ◽  
Breast Cancer Survivors ◽  
Ovarian Function ◽  
Future Fertility ◽  
Young Breast Cancer ◽  
Decisional Regret ◽  
Over Time

106 Background: Fertility is important to many young breast cancer survivors (YBCS), who face difficult decisions on whether to undergo fertility preservation prior to treatment. Because few longitudinal data assessing decisional regret are available, the objectives of this study were to assess longitudinal changes in decisional regret on fertility preservation following breast cancer diagnosis; determine if fertility preservation treatment decisions are related to decreased decisional regret. Methods: From 3 academic breast cancer programs, 169 YBCS younger than age 45 were recruited at diagnosis between 2009 and 2012 and followed prospectively for ovarian function. Participants completed questionnaires on fertility preservation choices and the Decisional Regret Scale (DRS) during study visits every 6 months for up to 5 years. DRS is scored 0 (no regret) to 100 (highest regret). DRS was dichotomized as none versus any decisional regret. Generalized linear models estimated the change in DRS over time and the association between patient characteristics and DRS. Results: Mean age at diagnosis was 38.7 (SD 4.8). Median total follow-up was 176 days (IQR 84 to 1415 days). Enrollment DRS was available for 89 women; 48% reported decisional regret about fertility preservation (median DRS=20). Participants worried about future fertility were more likely to report decisional regret (p=0.009). 31% underwent fertility preservation, but this was not associated with decisional regret (p=0.65). In repeated measures analysis for the entire cohort, no significant change in DRS occurred over this time period (OR 0.8, 95% CI 0.4-1.7). Worry about future fertility remained significantly associated with DRS over time (OR 55.1, 95% CI 7.7-395.1). Conclusions: In a cohort of YBCS, experiencing decisional regret about fertility preservation persists for years after diagnosis. Those worried about future fertility are more likely to experience decisional regret regarding fertility preservation.

scholarly journals Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors

Cancer ◽  
2010 ◽  
Vol 116 (3) ◽  
pp. 592-599 ◽  
Author(s):  
H. Irene Su ◽  
Mary D. Sammel ◽  
Jamie Green ◽  
Luke Velders ◽  
Corrie Stankiewicz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Ovarian Function ◽  
Inhibin B ◽  
Antimullerian Hormone ◽  
Antimüllerian Hormone

Assessment of ovarian function as an endpoint in breast cancer clinical trials: A systematic review.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e14098-e14098
Author(s):  
Wanyuan Cui ◽  
Prudence A. Francis ◽  
Sherene Loi ◽  
Martha Hickey ◽  
Catharyn Stern ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Ovarian Function ◽  
Premenopausal Women ◽  
Antral Follicle ◽  
Antral Follicle Count ◽  
Post Treatment ◽  
Phase 3 ◽  
Mesh Terms ◽  
Treatment Type

e14098 Background: Premature ovarian failure (POF) is an established adverse effect of chemotherapy for breast cancer (BC); little is known about the ovarian toxicity of newer treatments (e.g. PARPi, CDK4/6 inhibitors, immunotherapy, anti-HER2 therapy). This study examined whether contemporary BC (neo)adjuvant clinical trials will provide data on POF. Methods: Eligible studies were phase 3 (neo)adjuvant trials of pharmacologic agents aimed to reduce BC events, that enrolled premenopausal women between June 2008 - Sept 2019. MEDLINE and EMBASE were searched using MESH terms / keywords: “breast neoplasm” or “breast adj2 (cancer* or tumo?r* or carcinoma*)”, “adjuvant chemotherapy” or “neoadjuvant therapy” or “neoadjuvant” or “adjuvant”. Clinicaltrials.gov and EudraCT were searched using the filters “breast cancer”, “interventional studies”, “phase 3”. Data extracted from eligible trial publications, protocols and clinicaltrials.gov/EudraCT summaries, included whether each trial assessed the variables - post treatment pregnancy/birth, attempt at pregnancy, menstrual data, antral follicle count, FSH, LH, estrogen, progesterone and AMH levels. Results: Of 1665 trials screened, 141 were eligible. Investigational treatments included chemotherapy (71%), endocrine (20%), anti-HER2 (26%), immunotherapy (8%), CDK4/6 inhibitor (5%), PARPi (2%). Few trials (28%) assessed quality of life (QOL). Study chairs were from Nth America (19%), Europe (36%), Asia (43%); most (67%) were male. POF and fertility measures were prespecified endpoints in 9 (6%) and 0 trials respectively. Twenty (14%) trials collected POF and/or fertility data; post treatment pregnancy (11/20), amenorrhoea (6/20), estrogen (8/20), FSH (7/20), LH (5/20), AMH (3/20), and progesterone levels (1/20) and antral follicle count (3/20). Assessment of POF was associated with collection of QOL data (p = 0.02) but not with BC phenotype, timing, treatment type, or sex or nationality of study chair. Conclusions: POF measures are rarely prespecified endpoints and are infrequently collected in phase 3 BC (neo)adjuvant trials. Trialists should consider POF, given the potential for this data to enhance informed decision making for premenopausal patients.

scholarly journals Ovarian function after chemotherapy in young breast cancer survivors

2017 ◽  
Vol 24 (6) ◽  
pp. 494 ◽  
Author(s):  
K. Morarji ◽  
O. McArdle ◽  
K. Hui ◽  
G. Gingras-Hill ◽  
S. Ahmed ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Ovarian Function ◽  
Cross Sectional ◽  
Patient Counselling ◽  
Menstrual Cycles ◽  
Treated Breast ◽  
Young Breast Cancer ◽  
Treated Breast Cancer

Background As cure rates for breast cancer improve, there is increasing evidence that late effects of treatment—and impaired fertility in particular—are emerging as important concerns among young breast cancer survivors. Older reports have evaluated the occurrence of amenorrhea after treatment, but few data have been reported about the incidence of biochemical evidence for impaired ovarian function in patients who do not become overtly menopausal.Methods We conducted a cross-sectional study evaluating anti-Müllerian hormone (amh) in premenopausal chemotherapy-treated breast cancer survivors and control patients. Random serum levels of amh and other relevant clinical data were collected for 100 premenopausal chemotherapy-treated breast cancer survivors and 76 control subjects. Subgroup analyses were performed for women with regular menstrual cycles at the time of amh testing.Results After adjustment for age, amh was significantly lower in the overall group of patients receiving chemotherapy (p = 0.002) and in the subgroup reporting normal cycles (p = 0.03). Cyclophosphamide produced a significant dosedependent reduction in amh (p < 0.001); trastuzumab was associated with increased amh in survivors with normal cycles. Overall, serum amh in survivors was roughly equivalent to that measured in control patients 12 years older.Conclusions Young breast cancer survivors often experience significant impairment of ovarian function despite having normal menstrual cycles after treatment. Those results have important implications for patient counselling and the timing of possible referral to a fertility specialist.

Ovarian function and childbearing issues in breast cancer survivors

2007 ◽  
Vol 23 (11) ◽  
pp. 625-631 ◽  
Author(s):  
Angiolo Gadducci ◽  
Stefania Cosio ◽  
Andrea Riccardo Genazzani
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Ovarian Function

Biomarkers of amenorrhea and ovarian function in breast cancer survivors.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 9071-9071 ◽  
Author(s):  
Kathryn Jean Ruddy ◽  
Shari Gelber ◽  
Rulla M. Tamimi ◽  
Elizabeth S Ginsburg ◽  
Lidia Schapira ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Ovarian Function ◽  
Future Research ◽  
Bilateral Oophorectomy ◽  
Blood Draw ◽  
Ovarian Ablation ◽  
Therapy Decision ◽  
One Year

9071 Background: Ovarian function after treatment of early breast cancer may affect fertility, menopausal symptoms, endocrine therapy decision-making, and subsequent health and psychosocial concerns among young survivors. We aim to improve understanding of ovarian reserve in women with a history of breast cancer by comparing anti-mullerian hormone (AMH), estradiol (E2), and follicle-stimulating hormone (FSH) levels in survivors with and without amenorrhea, a surrogate for ovarian dysfunction and menopause. Methods: As part of an ongoing prospective multi-center cohort study, women diagnosed with breast cancer at age <41 have blood and surveys collected one year after diagnosis. Women who reported that they were receiving ovarian suppression or had undergone hysterectomy or bilateral oophorectomy/ovarian ablation were excluded. Amenorrhea was defined as >6 months between blood draw and last menstrual period. AMH, E2, and FSH levels were compared between those with and without amenorrhea using a Wilcoxon rank sum test with 2-sided p-values. Results: The first 199 eligible women with blood and survey data at one year were included in this analysis. Median age was 37 years (range 22-40). Seventy-two(36%) had received chemotherapy alone, 75 (38%) had received chemotherapy followed by tamoxifen (TAM), 25 (13%) had received TAM alone, and 10 (5%) reported TAM use but did not respond to chemotherapy items. Median AMH and E2 were lower and FSH was higher in women with amenorrhea, and these differences remained significant when those on and off TAM were analyzed separately (Table). Conclusions: AMH, E2, and FSH all are promising biomarkers for amenorrhea and residual ovarian function in young breast cancer survivors. Future research will evaluate whether AMH, E2, and FSH at baseline and early in the survivorship period predict ovarian function later. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document